PUBLIC COMPANY
saveASTELLAS
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Immutep, Molecular cut workforcesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Lilly shuffles business structure; Novartis writes off part of Avidity dealLilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.biopharma_dive · 3d ago
- Astellas bets up to $1.34B for option to advance Audax immuno-oncology assetAstellas Pharma could secure the exclusive global rights to Audax Biosciences’ DAX-044, an antibody-cytokine fusion therapy that activates the immune system in the vicinity of the tumor.biospace · 3d ago
- Astellas buys option on preclinical IL-12 cancer drug from Audax BiosciencesAstellas has taken an exclusive option to license a preclinical immuno-oncology asset from Australian biotech Audax Biosciences. The deal features $285 million that covers the upfront fee and a pay…endpoints · 3d ago
- Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woesAstellas has struck a deal for Audax Biosciences’ IL-12 program, committing up to $285 million in upfront and option fees to secure a chance to license the preclinical immuno-oncology program.fiercebiotech · 4d ago
- ‘The patient need is enormous’: Syntax programs stem cells into pancreatic beta cells in 4 daysChicago-based Syntax Bio believes it has cracked the code for turning stem cells into pancreatic beta cells in as little as four days.fiercebiotech · 4d ago
- ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 winTakeda has lifted the lid on the phase 3 win for its next-generation claudin18.2 drug, with the antibody-drug conjugate (ADC) demonstrating overall survival of 10.2 months.fiercebiotech · 8d ago
- Astellas links up with AI Proteins in $400M computational drug discovery dealJapan's Astellas Pharma has tapped Boston computational discovery company AI Proteins in a drug discovery deal potentially worth $400 million.fiercebiotech · 10d ago
- Exclusive: Astellas partners with Boston ‘miniproteins’ startupChris Bahl believes AI can help make tiny proteins capable of doing things that bigger and more traditional proteins like antibodies struggle to do. And now the Japanese drugmaker Astellas is buyin…endpoints · 11d ago
- Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagersThe Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tu…biospace · 17d ago
comments(0)
5-min edit window · permanent after that